11 completed, 3 recruiting, 2 terminated, 1 active not recruiting. 10 Phase 3, 9 Phase 2, 2 Phase 1.
Follow zilucoplan: new trials by email Literature Review of zilucoplan trials Research Report on zilucoplan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zilucoplan for Severe gMG Exacerbations Zilucoplan® - Generalized Myasthenia Gravis (gMG) | Phase 3 | Recruiting | Miriam Freimer | 15 | 2026-01-20 | 2026-08-28 |
| A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women Zilucoplan - Healthy Participants | Phase 1 | Recruiting | UCB Biopharma SRL | 15 | 2025-07-09 | 2026-08-27 |
| An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Zilucoplan - Generalized Myasthenia Gravis | Phase 3 | Enrolling by invitation | UCB Biopharma SRL | 8 | 2024-11-19 | 2026-10-02 |
| A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Zilucoplan - Generalized Myasthenia Gravis | Phase 2 / Phase 3 | Recruiting | UCB Biopharma SRL | 8 | 2024-10-16 | 2026-11-05 |
| A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis Zilucoplan - Generalized Myasthenia Gravis | Phase 3 | Completed | UCB Biopharma SRL | 31 | 2024-08-27 | 2026-03-27 |
| A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants Zilucoplan - Healthy Volunteers | Phase 1 | Completed | UCB Biopharma SRL | 14 | 2024-08-05 | 2026-01-06 |
| An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors zilucoplan (RA101495) - Generalized Myasthenia Gravis | Phase 3 | Completed | UCB Biopharma SRL | 26 | 2022-10-31 | 2025-09-03 |
| Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients Standard of care, Apremilast, Apremilast placebo - COVID-19 | Phase 3 | Completed | Amgen | 515 | 2020-11-24 | 2022-06-29 |
| HEALEY ALS Platform Trial - Regimen A Zilucoplan Zilucoplan, Matching Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Merit E. Cudkowicz, MD | 162 | 2020-07-29 | 2023-07-25 |
| HEALEY ALS Platform Trial - Master Protocol Zilucoplan, Verdiperstat, CNM-Au8 - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Active not recruiting | Merit E. Cudkowicz, MD | 1500 | 2020-06-14 | 2026-07-21 |
| Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure Zilucoplan®, Placebo - COVID-19 | Phase 2 | Completed | University Hospital, Ghent | 81 | 2020-05-22 | 2023-09-14 |
| Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis zilucoplan (RA101495) - Generalized Myasthenia Gravis | Phase 3 | Completed | UCB Biopharma SRL | 200 | 2019-12-23 | 2026-10-16 |
| Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy zilucoplan, Placebo - Immune Mediated Necrotizing Myopathy | Phase 2 | Terminated | Ra Pharmaceuticals | 27 | 2019-11-07 | 2022-07-27 |
| Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis zilucoplan (RA101495), Placebo - Myasthenia Gravis, Generalized | Phase 3 | Completed | Ra Pharmaceuticals, Inc. | 174 | 2019-09-17 | 2025-07-16 |
| Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis zilucoplan (RA101495), Placebo - Generalized Myasthenia Gravis | Phase 2 | Completed | Ra Pharmaceuticals | 45 | 2017-10-11 | 2022-07-27 |
| Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study Zilucoplan (RA101495) - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Terminated | Ra Pharmaceuticals, Inc. | 19 | 2017-07-17 | 2023-09-28 |
| Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab Zilucoplan (RA101495) - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Ra Pharmaceuticals | 3 | 2017-04-17 | 2022-07-27 |
| Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Zilucoplan (RA101495) - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Ra Pharmaceuticals | 26 | 2017-03-08 | 2022-07-27 |
Myasthenia Gravis (8) · Hemoglobinuria, Paroxysmal (3) · Amyotrophic Lateral Sclerosis (2) · COVID-19 (2) · Acute Lung Injury (1) · Hypoxia (1) · Respiratory Distress Syndrome (1) · Severe Acute Respiratory Syndrome (1)
UCB Biopharma SRL (7) · Ra Pharmaceuticals (4) · Merit E. Cudkowicz, MD (2) · Ra Pharmaceuticals, Inc. (2) · Amgen (1) · Miriam Freimer (1) · University Hospital, Ghent (1)
United States (14) · United Kingdom (8) · Canada (5) · Poland (5) · Germany (4) · Italy (4) · France (3) · Australia (2) · Finland (2) · Hungary (2) · Japan (2) · Netherlands (2) · New Zealand (2) · Norway (2) · South Korea (2)
Dr. Anita Hill (3) · Bart N Lambrecht, MDPhD (1) · Merit Cudkowicz (1) · Merit Cudkowicz, MD (1) · Miriam Freimer, MD (1)
PMID 37059508, PMID 38400914, PMID 39314260, PMID 40504283, PMID 32065623, PMID 33213529, PMID 34473343, PMID 35945604, PMID 37534517, PMID 38638673, PMID 39960672, PMID 40067754, PMID 40067755, PMID 40067821, PMID 40450840, PMID 40620733
2016 (2), 2023 (1)